Ageas completes its 2024-2025 share buy-back programme Ageas completes its 2024-2025 share buy-back programme On Thursday 31 July 2025, Ageas completed the share buy-back programme it announced on 28 August 2024. Between 16 September 2024 and 31 July 2025, Ageas has bought back 3,910,230 shares corresponding to 1.97 % of the total shares outstanding and totalling EUR 200 million (rounded). Together with other treasury shares held by Ageas, the total number of shares now owned amounts to 4.13 % of shares issued. The overview of the completed share buy-back programme is available on our ....
Ageas achève son programme de rachat d’actions 2024-2025 Ageas achève son programme de rachat d’actions 2024-2025 Ageas a achevé, le jeudi 31 juillet 2025, le programme de rachat d’actions annoncé le 28 août 2024. Entre le 16 septembre 2024 et le 31 juillet 2025, Ageas a procédé au rachat de 3.910.230 actions, représentant 1,97% du total des actions en circulation et un montant total arrondi d’EUR 200 millions. En ce compris les autres actions déjà détenues par Ageas, le montant total des actions désormais détenues par Ageas s’élève à 4,13% des actions émises. Le récapitulatif relatif a...
Ageas voltooit inkoopprogramma eigen aandelen 2024-2025 Ageas voltooit inkoopprogramma eigen aandelen 2024-2025 Op donderdag 31 juli 2025 voltooide Ageas het aandelen-inkoopprogramma dat op 28 augustus 2024 werd aangekondigd. Tussen 16 september 2024 en 31 juli 2025 kocht Ageas 3.910.230 aandelen in. Dit komt overeen met 1,97% van het totale aantal uitstaande aandelen en met een totaalbedrag van afgerond EUR 200 miljoen. Samen met de eigen aandelen die Ageas al in bezit had, komt het totale aantal aandelen dat Ageas nu aanhoudt op 4.13%. Het volledige overzicht van het aandelen-inkooppro...
Alfen: Preview - muddling through? Belgian telcos: Competition Authority investigation on Proximus/Orange Belgium MoU. Brunel International: 2Q25 below, 3Q25 outlook cut, cost savings protect FY25 estimates. Euronext: Another record set of results. Fugro: Sharper V-shape? GBL: Weak NAV performance, as expected. KBC Ancora: Cooperative CERA increasing its stake to 51.24%, using excess cash. UCB: Renewed US threats to cut drug prices. Umicore: 1H25 and guide broadly in-line, new S...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Keple...
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), New York (New York, Etats-Unis), le 31 juillet 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite non alcoolique ("NASH") et d’autres maladies avec un besoin médical non satisfait significatif, annonce aujourd’hui le bilan semestriel de son contrat de liquidité conclu avec Kepler Cheuvreux. Au titre du contrat de...
We upgrade our 2026 Bimzelx sales to be €0.9bn higher than consensus with conservative assumptions & and are now 11% above consensus on 2026 group sales & 19% on EBITDA. We upgrade our already above-consensus ‘27 EBITDA by 5%. Using our proprietary product-by-product Contribution Analysis, we show that the gross margin is highly sensitive to Bimzelx growth. We analyse the galvokimig data, which looks very strong Vs Dupi. Whilst UCB pipeline readouts & Moonlake risk will dominate specialists’ tho...
UCB's growth continues with 1H25 earnings increasing to € 3.49b, beating CSS expectations by approx. 8%. We note that Bimzelx performed significantly higher vs. expectations bringing in € 799m (CSS: € 615m) continuing its solid growth momentum. The company updated its FY25 guidance to revenue of at least € 7b based on a strong outlook for the remainder of the year. We reiterate our €214 TP and Accumulate.
AB InBev: 2Q25 results. Air France-KLM: Nice beat, let's see how FY25 finishes. AMG: Uptrend continues in 2Q25 with 23% EBITDA beat and guidance up to +US$200m. Aperam: Slight 2Q25 EBITDA beat, 3Q25 seen down QoQ. Arcadis: EBITA margin held up well in 2Q25, order intake mixed. Ayvens: 2Q25 results. Azelis: Soft but largely in-line 2Q25 with EMEA offsetting weaker APAC. Bekaert: 1H25 miss and lowered outlook to result in c.5% consensus downside. Corbion: Taking it to the wire. dsm...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.